These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 38170205)
1. An overlapping case of IgG4-related disease and systemic lupus erythematosus treated with belimumab: a case-based review. Iwamoto M; Asashima H; Sugita T; Kawashima F; Sugita N; Rai A; Kuroda Y; Kawashima A; Tabuchi D; Akao S; Sato R; Nishiyama T; Toko H; Honda F; Ohyama A; Kitada A; Abe S; Miki H; Hagiwara S; Kondo Y; Tsuboi H; Matsumoto I Rheumatol Int; 2024 Mar; 44(3):549-556. PubMed ID: 38170205 [TBL] [Abstract][Full Text] [Related]
2. A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. Yamamoto M; Aochi S; Suzuki C; Nakamura S; Murakami R; Ogawa Y; Takahashi H Lupus; 2019 May; 28(6):786-789. PubMed ID: 30917769 [TBL] [Abstract][Full Text] [Related]
3. IgG4-associated disease with systemic lupus erythematosus: A case report and review. Xie R; Li H; Wang X; Li X Clin Nephrol; 2024 Sep; 102(3):166-173. PubMed ID: 38836366 [TBL] [Abstract][Full Text] [Related]
4. Progression of immunoglobulin G4-related disease to systematic lupus erythematosus after gastric cancer surgery: A case report. Arai H; Hayashi H; Ogata S; Uto K; Saegusa J; Takahashi K; Koide S; Inaguma D; Hasegawa M; Yuzawa Y Medicine (Baltimore); 2018 Dec; 97(51):e13545. PubMed ID: 30572454 [TBL] [Abstract][Full Text] [Related]
5. A case of recurrent IgG4-related disease successfully treated with belimumab after remission of systemic lupus erythematosus. Katayama Y; Katsuyama T; Shidahara K; Nawachi S; Asano Y; Ohashi K; Miyawaki Y; Katsuyama E; Narazaki M; Matsumoto Y; Sada KE; Wada J Rheumatology (Oxford); 2022 Oct; 61(10):e308-e310. PubMed ID: 35595251 [No Abstract] [Full Text] [Related]
6. Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases. Nakayama K; Tamimoto Y; Nakayama T Mod Rheumatol Case Rep; 2023 Dec; 8(1):69-73. PubMed ID: 37718578 [TBL] [Abstract][Full Text] [Related]
7. A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. Fujita Y; Iwata S; Nakano K; Nakayamada S; Miyazaki Y; Kawabe A; Korekoda-Yoshinari H; Nawata A; Tanaka Y Mod Rheumatol Case Rep; 2022 Jun; 6(2):178-182. PubMed ID: 35084041 [TBL] [Abstract][Full Text] [Related]
8. IgG4-related disease administered dupilumab: case series and review of the literature. Kanda M; Kamekura R; Sugawara M; Nagahata K; Suzuki C; Takano K; Takahashi H RMD Open; 2023 Mar; 9(1):. PubMed ID: 36894196 [TBL] [Abstract][Full Text] [Related]
9. An Overlapping Case of IgG4-related Disease and Klinefelter Syndrome with Lupus-like Serological and Neurological Features: A Case Report and Literature Review. Takanashi S; Hanaoka H; Ota Y; Kaneko Y; Takeuchi T Intern Med; 2020 Oct; 59(20):2601-2609. PubMed ID: 32581168 [TBL] [Abstract][Full Text] [Related]
10. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report. Otani T; Iwamoto H; Yoshida Y; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hirata S; Sugiyama E; Hattori N J Asthma; 2022 Dec; 59(12):2395-2401. PubMed ID: 34937495 [No Abstract] [Full Text] [Related]
11. An Overlapping Case of IgG4-Related Disease and Systemic Lupus Erythematosus. Naramala S; Biswas S; Adapa S; Gayam V; Konala VM; Bose S J Investig Med High Impact Case Rep; 2019; 7():2324709619862297. PubMed ID: 31319713 [TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of belimumab in central nervous system demyelinating syndromes with systemic lupus erythematosus: A case series. Liu Y; Fan Q; Jia C; Wan Q; Yang H Medicine (Baltimore); 2023 Jun; 102(25):e34079. PubMed ID: 37352070 [TBL] [Abstract][Full Text] [Related]
13. Short-term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus. Wu C; Gong B Immun Inflamm Dis; 2022 Nov; 10(11):e716. PubMed ID: 36301032 [TBL] [Abstract][Full Text] [Related]
14. Belimumab for systemic lupus erythematosus. Singh JA; Shah NP; Mudano AS Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841 [TBL] [Abstract][Full Text] [Related]
15. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Guzman M; Hui-Yuen JS Drug Des Devel Ther; 2020; 14():2503-2513. PubMed ID: 32612353 [TBL] [Abstract][Full Text] [Related]
16. [The clinical characteristics of 346 patients with IgG Zhang PP; Zhao JZ; Wang M; Feng RE; Liu XW; Lai XM; Li XJ; Zeng JG; Shi HJ; Zhu HD; Xue W; Zhang H; Chen YY; Fei LY; Peng XF; Zeng FC; Zhang YM; Zhang W Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):644-649. PubMed ID: 28870031 [No Abstract] [Full Text] [Related]
18. Semiquantitative An SY; Sun BJ BMC Cardiovasc Disord; 2024 Feb; 24(1):122. PubMed ID: 38389040 [TBL] [Abstract][Full Text] [Related]
19. Belimumab in early systemic lupus erythematosus: A propensity score matching analysis. Lu C; He N; Dou L; Yu H; Li M; Leng X; Zeng X Immun Inflamm Dis; 2024 Aug; 12(8):e1362. PubMed ID: 39172013 [TBL] [Abstract][Full Text] [Related]
20. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]